Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants

Table 1

Phase III clinical trial on non-vitamin K antagonist oral anticoagulants.

Trial	Year	Drug	Type of the study	Sample ()	Mean TTR (%)	Mean CHA2DS2-VASc score	Follow-up (years)
RE-LY [27]	2009	Dabigatran	Open-label	Total patients 18,113; Men 11,514; Women 6,599	64	2.1	2.0
ROCKET-AF [28]	2011	Rivaroxaban	Double-blind	Total patients 14,264; Men 8,601; Women 5,663	55	3.5	1.9
ARISTOTLE [29]	2011	Apixaban	Double-blind	Total patients: 18,201; Men 11,785,; Women 6,416	62.2	2.1	1.8
ENGAGE AF-TIMI 48 [30]	2013	Edoxaban	Double-blind	Total patients: 21,105; Men 13,065; Women 8,040	64.9	2.8	2.8